Even during a time of trade conflict, there was considerable litigation and patent licensing activity with China, including a pronounced role in global markets for Chinese companies and in China for US companies. Patent disputes and licensing involved a diverse group of technologies. Chinese companies have become more active in SEP litigation overseas. The United States is an important venue for litigating overseas patent disputes with Chinese entities. Both the patent licensing and pharma data show the importance of tracking market value and trends to determine the real-world impact of IP-related policies.
Vringo’s NDA dispute with ZTE has been previously noted in this blog. The case in the Southern District of New York involved violation of a Non-Disclosure Agreement by alleging revealing confidential materials […]
On this Thursday, November 6, the University of California at San Diego will be hosting a lunchtime program ““Doing Business in China: New Developments in Intellectual Property Law and Enforcement” A luncheon panel […]